Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Cipla
Deal Size : Undisclosed
Deal Type : Collaboration
Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India
Details : Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 29, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Cipla
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orchid Pharma Receives DCGI Approval for Cefepime & Enmetazobactam Antibiotic
Details : Exblifep (cefepime/enmetazobactam) is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 13, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
